Changes in the Incretin Levels After Gastric Bypass
Keywords:
morbid obesity, type 2 diabetes, bariatric surgery, incretins.
Abstract
Most researchers support the important role of incretins, particularly glucagon-like peptide-1 in improving metabolic control in patients with type 2 diabetes after bariatric operations, mostly involving shunting. A positive effect of bariatric surgery for type 2 diabetes is known from numerous publications on the results of surgical treatment of morbid obesity and in this review we try to analyze the mechanisms of this effect.
References
1. Вaggio L., Drucker D. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007; 132: 2131-57.
2. Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, et al. Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis. The American Journal of Medicine 2009;122(3):248–256. doi: 10.1016/j.amjmed.2008.09.041.
3. Dedov I , Shestakova M, Melnichenko G., INTERDISCIPLINARY CLINICAL PRACTICE GUIDELINES "MANAGEMENT OF OBESITY AND ITS COMORBIDITIES" 2021;18(1):5-99
4. Fiucaneet al., 2011; Malik, Willett, & Hu, 2013
5. GBD 2013 Risk Factor Collaborators et al., 2015
6. Heymsfield & Wadden, 2017
7. Holst J., Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab. 2004; 287: E199-Е206.
8. Holst J., Vilsboll T., Deacon C. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol. 2009; 297: 127-36.
9. Guidone C., Manco M., Valera-Mora E. et al. Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes. 2006; 55: 2025-31.
10. Korner J., Bessler M., Inabnet W. et al. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis. 2007; 3: 597-601.
11. Laferrere B., Heshka S., Wang K. et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care. 2007; 30: 1709-16. 74.
12. Le Roux C., Welbourn R., Werling M. et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Annals of Surgery. 2007; 246(5): 780-85.
13. Nauck M. Unraveling the science of incretin biology. Am J Med. 2009; 122: S3-S10.
14. Neumiller J. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assos. 2009; 49(Suppl 1): S16-29
15. Laferrere B., Teixeira J., McGinty J. et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008; 93: 2479-85.
16. Огнева Н.А. Изменение продукции инкретинов и обмена кальция у пациентов с морбидным ожирением, перенесших билиопанкреатическое шунтирование: Дис. ... канд. мед. наук. Москва: ФГБУ ЭНЦ, 2014.
17. Rodieux F., Giusti V., D’ Alessio D. et al. Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release. Obesity (Silver Spring). 2008; 16: 298-305.
18. Rubino F., Gagner M., Gentileschi P. et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 2004; 240: 236-42.
19. Shak J., Roper J., Perez-Perez G. et al. The effect of laparoscopic gastric banding surgery on plasma levels of appetite-control, insulinotropic, and digestive hormones. Obes Surg. 2008; 18: 1097-98.
20. Schauer et al., 2016
21. Valverde I., Puente J., Martin-Duce A. et al. Changes in glucagon-like peptide-1 (GLP-1) secretion after biliopancreatic diversion or vertical banded gastroplasty in obese subjects. Obes Surg. 2005; 15: 387-97.
22. Whitson B., Leslie D., Kellogg T. et al. Entero-endocrine changes after gastric bypass in diabetic and nondiabetic patients: a preliminary study. Journal of Surgical Research. 2007; 1(141): 31-39.
2. Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, et al. Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis. The American Journal of Medicine 2009;122(3):248–256. doi: 10.1016/j.amjmed.2008.09.041.
3. Dedov I , Shestakova M, Melnichenko G., INTERDISCIPLINARY CLINICAL PRACTICE GUIDELINES "MANAGEMENT OF OBESITY AND ITS COMORBIDITIES" 2021;18(1):5-99
4. Fiucaneet al., 2011; Malik, Willett, & Hu, 2013
5. GBD 2013 Risk Factor Collaborators et al., 2015
6. Heymsfield & Wadden, 2017
7. Holst J., Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab. 2004; 287: E199-Е206.
8. Holst J., Vilsboll T., Deacon C. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol. 2009; 297: 127-36.
9. Guidone C., Manco M., Valera-Mora E. et al. Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes. 2006; 55: 2025-31.
10. Korner J., Bessler M., Inabnet W. et al. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis. 2007; 3: 597-601.
11. Laferrere B., Heshka S., Wang K. et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care. 2007; 30: 1709-16. 74.
12. Le Roux C., Welbourn R., Werling M. et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Annals of Surgery. 2007; 246(5): 780-85.
13. Nauck M. Unraveling the science of incretin biology. Am J Med. 2009; 122: S3-S10.
14. Neumiller J. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assos. 2009; 49(Suppl 1): S16-29
15. Laferrere B., Teixeira J., McGinty J. et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008; 93: 2479-85.
16. Огнева Н.А. Изменение продукции инкретинов и обмена кальция у пациентов с морбидным ожирением, перенесших билиопанкреатическое шунтирование: Дис. ... канд. мед. наук. Москва: ФГБУ ЭНЦ, 2014.
17. Rodieux F., Giusti V., D’ Alessio D. et al. Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release. Obesity (Silver Spring). 2008; 16: 298-305.
18. Rubino F., Gagner M., Gentileschi P. et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 2004; 240: 236-42.
19. Shak J., Roper J., Perez-Perez G. et al. The effect of laparoscopic gastric banding surgery on plasma levels of appetite-control, insulinotropic, and digestive hormones. Obes Surg. 2008; 18: 1097-98.
20. Schauer et al., 2016
21. Valverde I., Puente J., Martin-Duce A. et al. Changes in glucagon-like peptide-1 (GLP-1) secretion after biliopancreatic diversion or vertical banded gastroplasty in obese subjects. Obes Surg. 2005; 15: 387-97.
22. Whitson B., Leslie D., Kellogg T. et al. Entero-endocrine changes after gastric bypass in diabetic and nondiabetic patients: a preliminary study. Journal of Surgical Research. 2007; 1(141): 31-39.
Published
2023-04-16
How to Cite
1. Barno Khabibullaevna Shagazatova, & 2. Kudratova Nasiba Alisherovna. (2023). Changes in the Incretin Levels After Gastric Bypass. Central Asian Journal of Medical and Natural Science, 4(2), 446-450. Retrieved from https://cajmns.centralasianstudies.org/index.php/CAJMNS/article/view/1442
Section
Articles
